stockchase picture

Compiling comments that experts make about stocks while on public TV.

There are 0 registered members and 84 guests viewing this site

Company Index

List by Company Name

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

List by Symbol

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Abbott Labs

Stock Symbol: ABT-N

Last Price Recorded: 36.5900 on 2013-05-20 01:14:02

Globe 200 day average
Google Discussions (view only)
yahoo discussion
Date Signal Expert Opinion Price
2011-10-20 BUY Barry Schwartz Restructuring came as a big surprise. Good valuation at 10X earnings. Long track record of raising dividends. Only real competition is Johnson & Johnson (JNJ-N) but feels this one has better growth. If they do the spinoff, they will probably stick with the non-pharma side of the business, which will be the better growth.
 Price:
$54.050
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2011-10-19 HOLD Stan Wong The market likes the split. Going to split into pharma and medical space. 3.6% dividend. Hold on to it for the time being.
Price:
$53.250
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
DEFENSIVE
Owned:
No
2011-09-14 BUY Barry Schwartz Diversified Pharma with pharmaceuticals, nutritionals and medical devices. Trading at a lower valuation (11X earnings) with a higher dividend and better growth prospects than Johnson & Johnson (JNJ-N).
 Price:
$50.920
Subject:
NORTH AMERICAN - LARGE
Bias:
DEFENSIVE
Owned:
Yes
2011-08-31 BUY Gordon Reid Have grown earnings every single year since 1991. Only 10 or 11x earnings. Likes them in the health care space because they are diversified. Market is worried about their largest drug, whose patent expires in a few years. He doesn’t see it as a problem.
 Price:
$21.270
Subject:
US EQUITIES
Bias:
CAUTIOUS
Owned:
Yes
2011-08-02 PAST TOP PICK Christine Poole (A Top Pick July 26/10. Up 5.72%.) Diversified healthcare company. Branded drug division has Marot for arthritis etc., medical devices including stents and nutritional. Have also been making acquisitions in the branded generic space. Good diversity. About 20% of revenues come from emerging markets.
 Price:
$50.200
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2011-07-08 DON'T BUY Brian Acker, CA He has a model price of $57.97, an 8% upside. Good company but he sees a lot of value elsewhere.
 Price:
$53.330
Subject:
NORTH AMERICAN - LARGE (OIL/GAS)
Bias:
UNKNOWN
Owned:
No
2011-05-24 BUY Barry Schwartz Raised dividend 30+ years in a row. Is going to show 10% earnings growth over next 2-3 years. A good space. They got too cheap so there is an opportunity.
Price:
$53.330
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Unknown
2011-05-03 TOP PICK Barry Schwartz All different types of health care services and products. 11 times this year’s earnings. Nice valuation and entry point here.
 Price:
$52.850
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2011-05-02 PAST TOP PICK Christine Poole (A Top Pick April 26/10. Up 8.35%.) Have both generic and branded drug divisions. Making acquisitions to increase their emerging market exposure, which currently represent 25% of their revenues. Also has the number one share in the drug alluding stent business. Very strong nutritional business.
 Price:
$52.590
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2011-04-27 BUY Gordon Reid Only a part of their business is in the pharma. Biggest drug is Humera for rheumatoid arthritis, which doesn’t go off patent until 2016. Also have a strong nutritional business. Earnings have grown every single year since 1991. Trades at about 11X earnings. Almost 4% dividend.
 Price:
$52.180
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2011-03-16 BUY Gordon Reid Likes it. Patent on Humera goes off in 2016. 20 years in a row they increased earnings per share. Reasonable multiple. They are not getting the benefit of the doubt for the good work they are doing internationally. The health care sector is out of favour. Steadily increase the dividend.
 Price:
$46.710
Subject:
US EQUITIES
Bias:
OPTIMISTIC
Owned:
Yes
2011-02-02 HOLD Gordon Reid Annual succession of increased earnings since 1992 but not getting credit for what they are doing. Trades at about 10X earnings. Health care has been a tough sector to be in. Be patient and let the sector come back into favour and let the street endorse what they are doing. Street is worried about expiration of their major drug Humera but that doesn’t expire until 2016.
 Price:
$45.730
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
Yes
2010-12-15 PAST TOP PICK Gordon Reid (A Top Pick Jan 13/10. Down 10.82%.) Very consistent grower and still likes.
 Price:
$48.120
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2010-11-23 BUY Don Reed Recently checked back. Well managed and in good financial shape.
 Price:
$46.950
Subject:
GLOBAL EQUITIES
Bias:
OPTIMISTIC
Owned:
Yes
2010-11-19 BUY on WEAKNESS Hap (Robert) Sneddon FCSI Good entry point at the support level of around $46. If it corrects and holds at $46, that is pretty powerful. Crummy relative strength, which is a pretty good sign. Do a partial Buy at $46 and another at around $43 and a final one at $41.
 Price:
$47.400
Subject:
TECHNICAL ANALYSIS & MACRO STRATEGY
Bias:
UNKNOWN
Owned:
No
Showing 31 to 45 of 61 entries

No Comments.

You must be logged in to comment.